TMCC2

Across TCGA pan-cancer cohorts, TMCC2 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated TMCC2 data layer compared with 8 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher TMCC2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated TMCC2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and CESC show a favorable association.

PAAD, KIRP, and BLCA are the cancer types where TMCC2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.380	0.198	<.001	52	view →
KIRP	DFS	Quartile	II,III,IV	0.169	0.570	.007	47	view →
BLCA	OS	Quartile	All	0.317	0.594	.005	36	view →
KICH	OS	Median	III,IV	0.766	1.000	.006	35	view →
MESO	DFS	Tertile	All	0.265	0.453	.010	35	view →
UVM	OS	Median	III,IV	0.296	1.000	.005	34	view →
SKCM	OS	Median	IV	0.221	0.780	.004	25	view →
CESC	OS	Quartile	IV	0.799	0.290	.013	24	view →
ESCA	DFS	Quartile	All	1.000	0.343	.009	23	view →
LUSC	DFS	Tertile	III,IV	0.172	0.436	.002	22	view →
LGG	OS	Tertile	All	0.926	0.821	<.001	22	view →
UCS	DFS	Median	III,IV	0.572	0.270	.011	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

TMCC2–PAAD (DFS)

Open the PAAD breakdown →